Jasper Therapeutics, Inc. 8-K

What Happened

• On June 1, 2026, Jasper Therapeutics, Inc. announced via press release (furnished as Exhibit 99.1 to its Form 8-K) that its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. The disclosure was furnished under Regulation FD.

Key Details

• Date of announcement: June 1, 2026.
• Action taken: Board initiated a comprehensive review of strategic alternatives.
• Press release: Furnished as Exhibit 99.1 to the Form 8-K.
• Filing status: Information was furnished (not “filed”) under General Instructions B.2 of Form 8-K and is not subject to Section 18 liability or automatically incorporated by reference into other filings.

Why It Matters

• A Board-initiated strategic review is a material corporate action that may lead to significant decisions affecting company strategy and shareholder returns. The company did not specify which alternatives are being considered, any timeline, or whether any transaction will result. Investors should monitor subsequent SEC filings and company releases for updates and details.